
Product Data Sheet

Product Name: ERA63
 Cat. No.: GC31788

Chemical Properties

Cas. No. 343248-86-2

SMILES C#C[C@]1(O)CC[C@@]2([H])[C@]3([H])[C@H](C)CC4=C(CCC(C4)=C)[C@@]3([H])CC[C@]12C

Formula C₂₂H₃₀O M.Wt 310.47

Solubility Soluble in DMSO Storage Store at -20°C

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure

Background

ERA63 is a selective estrogen receptor α agonist.

The pharmacologic properties for the ER α agonist ERA-63 (Org 37663) have been shown efficacy in inflammatory models at 1.5 mg/kg. ERA-63 dose-dependently decreases the TT-specific response whereas treatment with the ER β -agonist ERB-79 has no effect on TT-specific swelling. ERA-63 inhibits the tetanus toxoid (TT)-specific DTH response in WT and ER β -/- mice but not in ER α -/- mice. ERA-63 inhibits the tetanus-specific delayed type hypersensitivity response in WT and ER β KO but not in the ER α KO mice. Therapeutic administration of the selective agonist ERA-63 decreases the clinical signs of arthritis dose-dependently. In addition, the AUC analysis over the 20-day treatment period reveals a significant dose-dependent reduction in the ERA-63-treated mice when compared with vehicle control[1]. After 28 days of treatment with dosages ranging from pharmacological up to clearly toxic levels, selected ERA-63 dose levels (0.167-0.2, 1.67-2 and 16.7-20 mg/kg) are expected to have comparable estrogenic activity to respective EE dose levels (0.05, 0.5 and 5 mg/kg)[2].

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

[1]. Dulos J, et al. Suppression of the inflammatory response in experimental arthritis is mediated via estrogen receptor alpha but not estrogen receptor beta. *Arthritis Res Ther.* 2010;12(3):R101. [2]. Janssen GB, et al. The evaluation of the immunomodulating properties of ERA-63 a pharmaceutical with estrogenic activity. *Toxicol Lett.* 2008 Aug 28;180(3):196-201.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA